As biosimilars continue to reshape the market, plan sponsors are looking for real savings – without added complexity.
ProAct’s new BioPathways™ Program delivers targeted, clinically-aligned utilization management that promotes FDA‑approved biosimilars first – with no additional fees for prior authorization or step therapy.
By guiding members toward clinically appropriate biosimilars like adalimumab and ustekinumab, plans can achieve meaningful savings today while preparing for a pipeline that will drive over $90B in exclusivity losses over the next five years. Simple. Scalable. Focused on what works – for plans and members.
